Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.52 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 3/20 | 0.42 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.42 |
| ▸ | HPGDS | O60760 | 5/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP7 | P09237 | 1/20 | 0.39 |
| ▸ | MMP10 | P09238 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1365943 | 1.00 | USP30 (0.52) | USP30DGAT2BACE1BACE2HPGDS | |
| SCHEMBL12142190 | 1.00 | USP30 (0.52) | USP30DGAT2BACE1BACE2HPGDS | |
| SCHEMBL12776517 | 0.90 | USP30 (0.52) | USP30DGAT2BACE1BACE2HPGDS | |
| SCHEMBL2072065 | 0.90 | USP30 (0.52) | USP30DGAT2BACE1BACE2HPGDS | |
| SCHEMBL2073036 | 0.90 | USP30 (0.52) | USP30DGAT2BACE1BACE2HPGDS | |
| SCHEMBL2072062 | 0.90 | USP30 (0.52) | USP30DGAT2BACE1BACE2HPGDS | |
| SCHEMBL1367638 | 0.89 | USP30 (0.53) | USP30HPGDSGABRA5 | |
| SCHEMBL1365962 | 0.85 | HPGDS (0.41) | HPGDS | |
| SCHEMBL12776503 | 0.79 | HPGDS (0.59) | USP30HPGDSGABRA5 | |
| SCHEMBL12776688 | 0.78 | HPGDS (0.54) | USP30HPGDSGABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067589-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067589-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | BLAKE TANISHA D | 2009-11-12 | — | — | US | disclosed |
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | BLAKE TANISHA D | 2009-11-12 | — | — | US | disclosed |
| US-7582643-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582643-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2009-09-01 | — | — | US | disclosed |
| WO-2008104869-A1 | NICOTINAMIDE DERIVATIVES AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | BLAKE TANISHA D | 2008-08-28 | — | — | US | disclosed |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | BLAKE TANISHA D | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | CYP11B2, CYP11B1, LTC4S | USP30 4116/4885DGAT2 1898/4885BACE1 767/4885 |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | CYP11B2, CYP11B1, LTC4S | USP30 4116/4885DGAT2 1898/4885BACE1 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.